Highest-materiality recent filing
CytomX and Regeneron expand collaboration; CytomX to receive $37M in target nomination payments
Amendment No. 4 adds up to eight new collaboration programs; Regeneron nominates first two.
CytomX Q1 rev $10.3M; cash $346.7M; Varseta-M dose optimization enrollment complete (40 pts)
Q1 revenue $10.3M vs $50.9M YoY; decrease driven by completion of BMS and Amgen collaborations.
CytomX closes public offering of ~47M shares/warrants, net proceeds ~$234.4M for pipeline
Sold 45,990,567 shares at $5.30 and pre-funded warrants for 1,179,245 shares at $5.29999 each.
CytomX reports 2025 revenue $76.2M, down 45% YoY; cash $137.1M; Astellas collaboration ends
Revenue $76.2M (down from $138.1M in 2024) on completion of BMS collaboration and lower collaboration milestones.
CytomX Q3 2025 revenue $6.0M (down 82% YoY); cash $143.6M; pipeline on track for key milestones
Total revenue $6.0M in Q3 2025 vs $33.4M in Q3 2024; cash, equivalents and investments $143.6M, runway to Q2 2027.
CytomX reports Grade 5 adverse event in CX-2051 Phase 1 trial; FDA notified, study continues
Single Grade 5 acute kidney injury occurred in patient with solitary kidney; event believed secondary to nausea, vomiting, diarrhea.
CytomX Q2 2025 cash $158.1M; positive CX-2051 Phase 1 data; $100M offering closed
Revenue $18.7M in Q2 2025 vs $25.1M in Q2 2024; operating expenses fell to $19.9M from $33.6M.
CytomX stockholders approve amended equity plan adding 4.38M shares; three directors elected
Stockholders elected three Class I directors: Sean McCarthy (16.4M for), Mani Mohindru (19.7M for), Zhen Su (19.7M for), terms until 2028.
CytomX nets $93.4M in underwritten common stock offering; 76.9M shares at $1.30
Sold 76,923,076 shares of common stock at $1.30/share, generating ~$93.4M in net proceeds after underwriting discounts and expenses.
CytomX Q1 revenue $50.9M; CX-2051 Phase 1 shows 28% ORR in advanced CRC
Q1 revenue $50.9M (up from $41.5M); operating expense $28.3M; cash $79.9M.
Revenue $138.1M for FY2024 vs $101.2M in FY2023 (+36%); cash and investments $100.6M vs $174.5M at year-end.
CytomX receives Nasdaq delisting notice for bid price non-compliance
Nasdaq notified CytomX on Feb 24, 2025 that common stock bid price stayed below $1.00 for 30 consecutive business days through Feb 21, 2025.
CytomX to cut ~40% of workforce, focus on CX-2051, extend cash runway
Workforce reduction of ~40%, primarily affecting G&A and non-partnered research staff, substantially complete in Q1 2025.
CytomX Q2 2024 cash $137.2M; revenue $25.1M; CX-904 update expected by year-end
Cash, equivalents and investments $137.2M at June 30, 2024, down from $150.3M at March 31, 2024.
CytomX Therapeutics appoints Chris Ogden as CFO effective June 15, 2024
Chris Ogden promoted from SVP Finance & Accounting to CFO, effective June 15, 2024.
CytomX Q1 revenue $41.5M, up 77% YoY; positive early CX-904 data
Q1 revenue $41.5M vs $23.5M YoY; cash $150.3M at Mar 31, 2024.
CytomX reports positive Phase 1a data for CX-904: no CRS, 33% response rate in pancreatic cancer
CX-904 demonstrated favorable safety: no CRS of any grade in step-dosing; no Grade >1 CRS overall.
FY2023 revenue $101.2M (up from $53.2M in 2022); operating expenses $107.7M (down from $154.5M).
CytomX Q3 revenue $26.4M, cash $194.1M; pipeline milestones on track
Revenue $26.4M vs $11.1M YoY; cash $194.1M (includes ~$30M from BVF financing, $16.8M Q3 burn).
CytomX Therapeutics regains exclusive worldwide rights to ADC CX-2029 from AbbVie
Regained full worldwide rights to develop CX-2029, a CD71-targeting conditionally activated antibody drug conjugate.
CytomX Q2 revenue $24.7M (up 91% YoY); cash runway into H2 2025 after $30M financing
Cash, equivalents & investments $180.9M at June 30, 2023; $30M gross financing from BVF closed July 2023.
CytomX raises $30M via private placement of units with warrants
Gross proceeds of $30M from unit sale at $2.08 each; closing expected July 3, 2023.
CytomX Q1 revenue $23.5M vs $9.0M YoY; cash $204.5M; pipeline advances
Revenue $23.5M in Q1 2023, up from $9.0M Q1 2022, driven by BMS project progress, Astellas milestone, and AbbVie termination revenue recognition.
CytomX FY2022 revenue $53.2M; cash $194M; AbbVie terminates CX-2029; new Moderna/Regeneron deals
FY2022 revenue $53.2M (+43% YoY); cash $194M vs $305M at Dec 2021.
CytomX says SVB exposure immaterial; cash near FDIC limit, $917K letter of credit
Operating cash at SVB at or near FDIC-insured limit of $250,000.
CytomX restates 2018-2021 annual and 2018-2022 quarterly financials due to revenue recognition error
Restatement affects timing of revenue from collaborations with Bristol-Myers Squibb, Astellas, AbbVie, and Amgen.
CytomX inks $35M upfront deal with Moderna for mRNA-Probody therapies; milestones up to $1.2B
Upfront payment of $35M includes $5M pre-paid research funding; potential milestones total $1.2B.
CytomX and Regeneron enter $30M upfront cancer bi-specific collaboration; up to $2B milestones
CytomX receives $30M upfront from Regeneron; eligible for up to $2B in development/regulatory milestones.
CytomX Q3 cash falls to $194.3M; revenue $16.9M; restructuring $7.1M; IND targets set for 2023
Cash and investments $194.3M as of Sep 30, 2022, down from $305.2M at Dec 31, 2021.
CytomX Q2 2022 revenue $18M; cash $228M; restructuring extends runway to 2025
Cash and investments $228M at June 30, 2022, down from $305M at Dec 31, 2021.
CytomX cuts ~40% of staff, $10M restructuring charge; COO, CFO, CMO to depart
Workforce reduction of ~40% primarily in development and G&A; completion expected by Q4 2022.
Arm A in HR+/HER2- breast cancer met primary endpoint: ORR 15% (central review) in 47 patients unselected for CD166 expression.
CytomX Q1 2022 revenue $17.1M; cash $263M; pipeline data expected H2 2022
Cash, equivalents and investments $263M at March 31, 2022, down from $305M at Dec 31, 2021.
CytomX reports Q4 rev $19.7M, cash $305.2M; CX-2029 18.8% ORR, CX-904 IND allowed
Cash and equivalents $305.2M at Dec 31, 2021 vs $316.1M at Dec 31, 2020.
CFO Carlos Campoy begins temporary personal leave effective Feb 14, 2022, but remains CFO and principal financial officer.
On July 24, 2026, Charles Fuchs, M.D., M.P.H., was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective immediately, as a Class II director
On January 30, 2025, Jeffrey Landau, Senior Vice President, Chief Business Officer, and Head of Strategy, of CytomX Therapeutics, Inc. (the “Company”) and the Company agreed that Mr. Landau’s employment by the Company would terminate, effective February 7, 2025.
On June 12, 2024, CytomX Therapeutics, Inc. (the “Company”) appointed Chris Ogden to serve as the Company’s Chief Financial Officer effective June 15, 2024 (the “Effective Date”).
On March 20, 2024, Zhen Su, M.D., M.B.A., was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective March 20, 2024, as a Class I director, with an initial term expiring at the Company’s 2025 annual meeting of stockholders, filling a vacancy.
the planned departure of Carlos Campoy, the Company's SVP, Chief Financial Officer and former principal financial officer and principal accounting officer, whose employment is expected to terminate effective as of September 30, 2022.
designated Chris Ogden, the Company's Senior Vice President, Finance and Accounting, to assume the responsibilities of principal financial officer and principal accounting officer, effective immediately
the employment of Carlos Campoy, the Company’s SVP, Chief Financial Officer, and Alison Hannah, M.D., the Company’s SVP, Chief Medical Officer, is expected to terminate effective as of September 30, 2022
the employment of Carlos Campoy, the Company’s SVP, Chief Financial Officer, and Alison Hannah, M.D., the Company’s SVP, Chief Medical Officer, is expected to terminate effective as of September 30, 2022
the employment of Amy Peterson, M.D., the Company’s President and Chief Operating Officer, is expected to terminate effective September 12, 2022
On April 11, 2022, John A. Scarlett, M.D. informed CytomX Therapeutics, Inc. (the “Company”) of his retirement from the Company’s board of directors, effective when his current term expires at the Company’s next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022.
On March 23, 2022, CytomX Therapeutics, Inc. (the “Company”) announced the retirement of Frederick W. Gluck from the Company’s board of directors, effective as of June 30, 2022.
In connection with Mr. Campoy’s personal leave of absence, the Company’s Board of Directors designated Chris Ogden, the Company’s Vice President, Finance and Accounting, to assume the responsibilities of interim principal accounting officer, effective February 14, 2022.
Max materiality 0.85 · Median 0.65 · Most common event earnings